This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment — if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
TaylorA.L., ZiescheS., YancyC.Combination of isosorbide-dinitrate and hydralazine in blacks with heart failure. N Engl J Med.20041; 351: 2049–2057.
2.
CohnJ.N., ArchibaldD.G., ZiescheS.Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med.1986; 314: 1547–1552.
3.
CohnJ.N., JohnsonG., ZiescheS.A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med.1991; 325: 303–310.
4.
FrancisG.S.Pathophysiology of chronic heart failure. Am J Med.2001; 110: Suppl 7A: 37S–46S.
5.
MehraM.R., UberP.A., PotluriS.Renin angiotensin aldosterone and adrenergic modulation in chronic heart failure: contemporary concepts. Am J Med Sci.2002; 324: 267–275.
6.
SharmaR., DavidoffM.N.Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail.2002; 8: 165–172.
7.
KeithM., GeranmayeganA., SoleM.J.Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol.1998; 31: 1352–1356.
8.
PrabhuS.D.Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res.2004; 94: 1155–1557.
9.
JanssensS., PokreiszP., SchoonjansL.Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res.2004; 94: 1256–1262.
10.
GogiaH., MehraA., ParikhS.Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol.1995; 26: 1575–1580.
11.
MunzelT., KurzS., RajagopalanS.Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest.1996; 98: 1465–1470.
12.
GillumR.F.Pathophysiology of hypertension in blacks and whites. A review of the basis of racial blood pressure differences. Hypertension.1979; 1: 468–475.
13.
CarsonP., ZiescheS., JohnsonG., CohnJ.N.Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail.1999; 5: 178–187.
14.
ExnerD.V., DriesD.L., DomanskiM.J., CohnJ.N.Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med.2001; 344: 1351–1357.
15.
CardilloC., KilcoyneC.M., CannonRO3rd, PanzaJ.A.Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension.1998; 31: 1235–1239.
16.
SteinC.M., LangC.C., NelsonR.Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther.1997; 62: 436–443.
17.
KalinowskiL., DobruckiI.T., MalinskiT.Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation.2004; 109: 2511–2517.
18.
RectorT.S., KuboS.H., CohnJ.N.: Patients’ self-assessment of their congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire. Heart Failure.1987; Oct/Nov: 198–209.
19.
American Heart Association.Heart Disease and Stroke Statistics-2005 Update.Dallas, Texas: American Heart Association; 2005.
20.
American Heart Association's top ten advances for 2004.www.american-heart.org. AHA news. December 23, 2004.
21.
BlocheM.G.Race-based therapeutics. N Engl J Med.2004; 351: 2035–2037.
22.
KahnJ.How a drug becomes “ethnic”: law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics.2004; 4: 1–46.
